Aerie Pharmaceuticals (AERI +2.9%) was initiated by Guggenheim analyst Dana Flanders with a Buy rating and price target of $20, indicating a upside of 67.8% from current levels.
Wall Street Analysts Rating is Bullish.
Aerie is expanding franchise in Japan, a $0.8B glaucoma market, market share 57 MM TRx, as Phase 3 trials expected to commence in Q4; currently exploring partnering opportunities.
Also expanding Aerie franchise in Europe, $1B glaucoma market, market share 105 MM units; Mercury 3 topline readout in Q3-results to inform commercialization strategy; Ireland plant approved for U.S. production.
Advancing Pipeline (Read More: Investor Presentation)
https://seekingalpha.com/news/3612257-aerie-initiated-buy-guggenheim
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.